Centric Wealth Management Purchases Shares of 796,723 MAIA Biotechnology, Inc. $MAIA

Centric Wealth Management acquired a new position in shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 796,723 shares of the company’s stock, valued at approximately $1,107,000.

A number of other institutional investors have also added to or reduced their stakes in MAIA. Geode Capital Management LLC grew its stake in MAIA Biotechnology by 3.6% in the second quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock valued at $400,000 after acquiring an additional 7,746 shares during the period. Marshall Wace LLP acquired a new position in shares of MAIA Biotechnology during the second quarter worth approximately $29,000. Ritholtz Wealth Management acquired a new position in shares of MAIA Biotechnology during the fourth quarter worth approximately $35,000. Jane Street Group LLC bought a new position in shares of MAIA Biotechnology in the 2nd quarter worth $52,000. Finally, PVG Asset Management Corp bought a new position in shares of MAIA Biotechnology in the 1st quarter worth $46,000. 5.65% of the stock is owned by institutional investors and hedge funds.

MAIA Biotechnology Trading Up 4.5%

NYSEAMERICAN MAIA opened at $1.40 on Friday. The company has a fifty day simple moving average of $1.36 and a 200 day simple moving average of $1.51. MAIA Biotechnology, Inc. has a 12-month low of $0.87 and a 12-month high of $3.19. The company has a market cap of $85.16 million, a P/E ratio of -2.26 and a beta of 0.24.

Insiders Place Their Bets

In other MAIA Biotechnology news, Director Stan Smith acquired 75,000 shares of the company’s stock in a transaction on Monday, June 1st. The shares were purchased at an average cost of $1.34 per share, with a total value of $100,500.00. Following the completion of the purchase, the director owned 1,519,178 shares of the company’s stock, valued at approximately $2,035,698.52. This represents a 5.19% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Vlad Vitoc acquired 72,700 shares of MAIA Biotechnology stock in a transaction dated Monday, June 1st. The shares were acquired at an average price of $1.39 per share, with a total value of $101,053.00. Following the completion of the acquisition, the chief executive officer directly owned 976,121 shares of the company’s stock, valued at approximately $1,356,808.19. The trade was a 8.05% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 149,700 shares of company stock worth $204,233 over the last ninety days. Insiders own 19.81% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.